Semaglutide 20mg

Overview

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist sharing 94% sequence homology with native human GLP-1. It is chemically modified to include a C18 fatty diacid side chain and specific amino acid substitutions that confer resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, making it a stable and reproducible tool compound for controlled laboratory research applications.

Scientific investigation of Semaglutide in controlled experimental settings focuses on its biochemical interactions with pancreatic beta-cells, insulin signaling pathways, and central nervous system receptors involved in appetite regulation pathway research. All applications are strictly confined to in-vitro and in-vivo animal research contexts and do not imply clinical, cosmetic, or therapeutic use.

Biochemical Characteristics

• Peptide Sequence: Modified GLP-1 (7-37) backbone with acylation
• Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEA-AEEA-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
• Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
• Molecular Weight: 4,113.58 g/mol
• PubChem CID: 56843331
• CAS Number: 910463-68-2

Semaglutide is a modified 31-amino acid peptide incorporating critical structural modifications including substitution of Alpha-aminoisobutyric acid (Aib) at position 8 to prevent enzymatic degradation, and acylation of the lysine residue at position 26 with a spacer and C18 fatty diacid chain. This fatty acid moiety promotes non-covalent binding to plasma albumin, significantly extending the molecule's stability in experimental environments and making it a valuable tool compound for chronic exposure studies in controlled laboratory models.

Biochemical analyses demonstrate that Semaglutide exhibits high affinity and selectivity for the GLP-1 receptor. Upon binding in experimental systems, it activates downstream signaling cascades analogous to the native ligand but with a substantially prolonged half-life profile.

Research Applications

Semaglutide is utilized in laboratory research to investigate glucose homeostasis pathway dynamics, insulin secretion mechanisms, and lipid metabolism endpoints. Experimental systems include:

• Diet-induced obesity (DIO) murine research models
• Pancreatic islet cell culture systems
• Gastric emptying rate measurement assays
• Neuroinflammation and neuroprotection pathway research in rodent neurodegeneration models
• Cognitive function marker assessment in controlled preclinical paradigms
• Hepatic steatosis reduction pathway investigation
• Cardiovascular marker modulation under controlled experimental conditions
• Comparative incretin mimetic benchmark studies in preclinical research systems

Pathway & Mechanistic Context

Mechanistic studies document Semaglutide as a specific ligand for the GLP-1 receptor in experimental systems. Receptor binding initiates a signaling cascade involving:

• Adenylyl cyclase activation
• Cyclic adenosine monophosphate (cAMP) accumulation
• Protein kinase A (PKA) activation and downstream transcriptional activity

Gene-expression analyses further demonstrate that Semaglutide influences transcriptional networks associated with insulin gene transcription and beta-cell proliferation markers in controlled laboratory settings. Additional mechanistic research areas include:

• Adipose tissue pathway modeling — lipolysis and energy uptake pathway modulation
• Central nervous system receptor activation research — hypothalamic and brainstem receptor interaction studies
• Insulin sensitivity pathway dynamics in defined experimental models
• Lipid metabolism and hepatic signaling pathway investigation

Preclinical Research Summary

Preclinical investigations of Semaglutide include extensive in-vivo studies across rodent and non-human primate research models. Commonly evaluated experimental endpoints include:

• Body weight trajectory and composition endpoint assessments
• Glycemic regulation parameters including HbA1c-equivalent markers
• Pancreatic beta-cell mass preservation indicators
• Food intake regulation pathway endpoints
• Gastric emptying dynamics under defined experimental conditions
• Insulin sensitivity markers in controlled research models
• Hepatic steatosis and liver function marker assessments
• Cardiovascular parameter endpoint modeling

Semaglutide is also frequently utilized as a benchmark reference compound in comparative studies evaluating novel incretin mimetics in preclinical research systems. All findings are presented exclusively as laboratory observations and do not imply clinical or therapeutic outcomes of any kind.

Form & Analytical Testing

Semaglutide is supplied as a synthetic research-grade peptide for controlled laboratory workflows. Product identity and purity are confirmed using:

• HPLC — purity profiling and lot consistency
• Mass Spectrometry (MS) — molecular identity confirmation

Purity & Quality

• ≥99% Purity — HPLC Verified
• Independently tested by accredited third-party laboratory
• Certificate of Analysis (CoA) available for every batch

Research Use Only (RUO) Notice

All products are furnished strictly for in-vitro laboratory research use only. These materials are not medicines or drugs and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.

All Semaglutide research compounds supplied by P1 Peptides are produced using lyophilization — also known as cryodesiccation — a specialized dehydration process widely employed in the manufacture of research-grade synthetic peptide materials.

During this process, the peptide is first frozen and then subjected to reduced pressure conditions, allowing residual moisture to sublimate directly from solid to vapor phase. This yields a stable, crystalline dry powder that preserves full structural integrity of the peptide compound throughout the storage period.

In its lyophilized form, Semaglutide research compounds remain stable for up to 3–4 months when stored properly under recommended conditions prior to reconstitution.

Reconstitution

When research protocols require reconstitution, Semaglutide is typically prepared using bacteriostatic water under controlled laboratory conditions. Once reconstituted, the peptide solution must be refrigerated to maintain compound stability. Reconstituted solutions are generally stable for up to 30 days when stored appropriately under refrigeration.

All reconstitution procedures should be carried out in accordance with standard laboratory protocols applicable to synthetic peptide research materials.

Recommended Storage Guidelines

The following storage parameters are recommended to maintain compound integrity throughout the research lifecycle:

Short-Term Storage — Unopened Lyophilized Vials

• Upon Receipt — Store in a cool, dry environment away from direct light and heat sources
• Short-Term Use (immediate use to several weeks or months) — Refrigeration below 4°C (39°F) is generally sufficient to maintain compound integrity
• Room Temperature Storage — Lyophilized Semaglutide is typically stable at room temperature for several weeks, making ambient storage acceptable for short-term laboratory use prior to reconstitution

Long-Term Storage — Unopened Lyophilized Vials

• Extended Storage (several months to years) — Freezing at −80°C (−112°F) is the preferred method for preserving compound stability and structural integrity over extended periods

Post-Reconstitution Storage

• Store reconstituted solutions under refrigeration below 4°C (39°F), away from direct light
• Do not freeze reconstituted solutions
• Discard any unused reconstituted material after 30 days or upon observation of cloudiness, discoloration, or particulate matter

Additional Laboratory Guidance

For specific storage requirements applicable to this research compound, researchers should consult the Certificate of Analysis (CoA) provided with each batch, as well as applicable peer-reviewed literature and institutional laboratory protocols governing synthetic peptide handling and storage procedures.

Research Use Only (RUO) Notice

All products are furnished strictly for in-vitro laboratory research use only. These materials are not medicines or drugs and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.